4Basebio PLC banner
4

4Basebio PLC
F:88Q

Watchlist Manager
4Basebio PLC
F:88Q
Watchlist
Price: 6.4 EUR Market Closed
Market Cap: €82m

Wall St Price Targets

88Q Price Targets Summary
4Basebio PLC

Wall Street analysts forecast 88Q stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 88Q is 21.74 EUR with a low forecast of 21.52 EUR and a high forecast of 22.38 EUR.

Lowest Forecast
Price Target
21.52 EUR
236% Upside
Average Forecast
Price Target
21.74 EUR
240% Upside
Highest Forecast
Price Target
22.38 EUR
250% Upside
4Basebio PLC Competitors:
Price Targets

Revenue
Forecast

19% / Year
Past Growth
131% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss
19% / Year
Past Growth
131% / Year
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Over the last 4 years, the compound annual growth rate for Revenue has been 19%. The projected CAGR for the next 4 years is 131%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-21%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-21%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 88Q's stock price target?
Price Target
21.74 EUR

According to Wall Street analysts, the average 1-year price target for 88Q is 21.74 EUR with a low forecast of 21.52 EUR and a high forecast of 22.38 EUR.

What is the Revenue forecast for 4Basebio PLC?
Projected CAGR
131%

Over the last 4 years, the compound annual growth rate for Revenue has been 19%. The projected CAGR for the next 4 years is 131%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett